Trials / Completed
CompletedNCT02122484
Colchicine in Coronary Artery Bypass Graft (CABG)
Study of Anti-inflammatory Treatment With Colchicine in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery to Reduce Reperfusion Damage
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- G.Gennimatas General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colchicine | colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-06-01
- Completion
- 2014-11-01
- First posted
- 2014-04-24
- Last updated
- 2014-11-11
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT02122484. Inclusion in this directory is not an endorsement.